Literature DB >> 21719778

Comorbidities in the aging breast cancer population: are current assessments leading to improved outcomes?

Worta McCaskill-Stevens, Jeffrey S Abrams.   

Abstract

Entities:  

Mesh：

Year:  2011        PMID： 21719778      PMCID： PMC3143423          DOI： 10.1093/jnci/djr239

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  6 in total

1.  Predictors of competing mortality in early breast cancer.

Authors:  Loren K Mell; Jong-Hyeon Jeong; Michael A Nichols; Blase N Polite; Ralph R Weichselbaum; Steven J Chmura
Journal:  Cancer       Date:  2010-08-24       Impact factor: 6.860

2.  Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology Study.

Authors:  Lazzaro Repetto; Lucia Fratino; Riccardo A Audisio; Antonella Venturino; Walter Gianni; Marina Vercelli; Stefano Parodi; Denise Dal Lago; Flora Gioia; Silvio Monfardini; Matti S Aapro; Diego Serraino; Vittorina Zagonel
Journal:  J Clin Oncol       Date:  2002-01-15       Impact factor: 44.544

3.  The influence of comorbidities on overall survival among older women diagnosed with breast cancer.

Authors:  Jennifer L Patnaik; Tim Byers; Carolyn Diguiseppi; Thomas D Denberg; Dana Dabelea
Journal:  J Natl Cancer Inst       Date:  2011-06-30       Impact factor: 13.506

4.  Older breast cancer survivors: geriatric assessment domains are associated with poor tolerance of treatment adverse effects and predict mortality over 7 years of follow-up.

Authors:  Kerri M Clough-Gorr; Andreas E Stuck; Soe Soe Thwin; Rebecca A Silliman
Journal:  J Clin Oncol       Date:  2009-12-14       Impact factor: 44.544

Review 5.  Comprehensive geriatric assessment for older patients with cancer.

Authors:  Martine Extermann; Arti Hurria
Journal:  J Clin Oncol       Date:  2007-05-10       Impact factor: 44.544

6.  Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer.

Authors:  Cynthia Owusu; Diana S M Buist; Terry S Field; Timothy L Lash; Soe Soe Thwin; Ann M Geiger; Virginia P Quinn; Floyd Frost; Marianne Prout; Marianne Ulcickas Yood; Feifei Wei; Rebecca A Silliman
Journal:  J Clin Oncol       Date:  2007-12-10       Impact factor: 44.544
  6 in total
  5 in total

1.  Applying pre-participation exercise screening to breast cancer survivors: a cross-sectional study.

Authors:  Lotachukwu T Igwebuike; Xiaochen Zhang; Justin C Brown; Kathryn H Schmitz
Journal:  Support Care Cancer       Date:  2017-12-19       Impact factor: 3.603

2.  Comorbidities and breast cancer survival: a report from the Shanghai Breast Cancer Survival Study.

Authors:  Sarah Nechuta; Wei Lu; Ying Zheng; Hui Cai; Ping-Ping Bao; Kai Gu; Wei Zheng; Xiao Ou Shu
Journal:  Breast Cancer Res Treat       Date:  2013-04-19       Impact factor: 4.872

3.  Comorbidities and cardiovascular disease risk in older breast cancer survivors.

Authors:  Reina Haque; Marianne Prout; Ann M Geiger; Aruna Kamineni; Soe Soe Thwin; Chantal Avila; Rebecca A Silliman; Virginia Quinn; Marianne Ulcickas Yood
Journal:  Am J Manag Care       Date:  2014       Impact factor: 2.229

4.  Co-morbidity and predictors of health status in older rural breast cancer survivors.

Authors:  Andres Azuero; Rachel Benz; Patrick McNees; Karen Meneses
Journal:  Springerplus       Date:  2014-02-20

5.  Living well after breast cancer randomized controlled trial protocol: evaluating a telephone-delivered weight loss intervention versus usual care in women following treatment for breast cancer.

Authors:  Marina M Reeves; Caroline O Terranova; Jane M Erickson; Jennifer R Job; Denise S K Brookes; Nicole McCarthy; Ingrid J Hickman; Sheleigh P Lawler; Brianna S Fjeldsoe; Genevieve N Healy; Elisabeth A H Winkler; Monika Janda; J Lennert Veerman; Robert S Ware; Johannes B Prins; Theo Vos; Wendy Demark-Wahnefried; Elizabeth G Eakin
Journal:  BMC Cancer       Date:  2016-10-28       Impact factor: 4.430
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.